Fredrik Järrsten
Direttore Finanziario/CFO presso OREXO AB
Patrimonio netto: 38 109 $ in data 30/04/2024
Provenienza dei contatti di primo grado di Fredrik Järrsten
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
16
| Public Company | Pharmaceuticals: Major | 16 |
| Public Company | Financial Conglomerates | 13 | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
2
| Operating Division | Investment Managers | 2 |
Aleris Holding AB
 Aleris Holding AB Medical/Nursing ServicesHealth Services Aleris Holding AB engages in health sector. It provides services in healthcare and mental health on behalf of municipalities, county councils and insurance companies. The company was founded in March 2005 and is headquartered in Stockholm, Sweden.
2
| Holding Company | Medical/Nursing Services | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Fredrik Järrsten tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| University of Uppsala | College/University | Undergraduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| Karolinska Institutet | College/University | Chairman Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree | |
AnaCardio AB
 AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| KCIF Fund Management AB | Director/Board Member Chairman Director/Board Member | ||
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Director/Board Member | |
Perma Ventures AB
 Perma Ventures AB Investment ManagersFinance Perma Ventures AB provides financial advisory services. The private company is based in Stockholm, Sweden. | Investment Managers | Director/Board Member Director/Board Member | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| University of Stockholm | College/University | Graduate Degree Undergraduate Degree | |
| KD Incentive AB | Director/Board Member Director/Board Member | ||
| University of Lund | College/University | Doctorate Degree Graduate Degree | |
Karolinska Institutet Holding AB
 Karolinska Institutet Holding AB Investment Trusts/Mutual FundsMiscellaneous Part of Karolinska Institutet Holding AB, Nätverk Karolinska Institutet Science Park AB (KISP) facilitates interaction between academia and industry on Campus Solna. The private company is based in Solna, Sweden. KISP collaborates closely with Karolinska Institutet, Akademiska Hus, and AWL to organize seminars, workshops, and networking events that help researchers, startups, and established companies connect and gain new insights. The CEO of the Swedish company is Karl Johan Ingvar Weigelt. | Investment Trusts/Mutual Funds | Chief Executive Officer General Counsel | |
| AEROCRINE AB | Electronic Equipment/Instruments | Director/Board Member Founder | |
| PROMIMIC AB | Medical Specialties | Director/Board Member Director/Board Member | |
invoX Pharma Ltd.
 invoX Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., invoX Pharma Ltd. is a British biopharmaceutical company. The private company is based in Kingston-upon-Thames, UK. The company was founded in 2021. Benjamin Toogood has been the CEO of the company since 2023. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| SINO BIOPHARMACEUTICAL LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal Chairman | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Esselte AB
 Esselte AB Office Equipment/SuppliesProducer Manufacturing Esselte AB manufactures office solutions. It sells office products and graphics products. The company was founded on April 18, 1913 and is headquartered in Solna, Sweden. | Office Equipment/Supplies | General Counsel | |
Biomatcell AB
 Biomatcell AB BiotechnologyHealth Technology Biomatcell AB operates as a holding company that commercializes inventions in the fields of biomaterial science and cell therapy by licensing its inventions and creating spin-off companies. It develops three-dimensional biomaterial scaffold geometries in bioactive ceramics and metals. It markets products and services based on research in the field of biomaterials and stem cells and patenting new ideas in the same area. The company was founded on May 11, 2004 and is headquartered in Gothenburg, Sweden. | Biotechnology | Director/Board Member | |
| Sjukvårdsleverantörernas Service AB | Chief Executive Officer | ||
Cure Cancer Foundation
 Cure Cancer Foundation Miscellaneous Commercial ServicesCommercial Services Cure Cancer Foundation operates as a cancer care foundation. The private company is based in Austin, TX. | Miscellaneous Commercial Services | Director/Board Member | |
| AB INDUSTRIVÄRDEN | Financial Conglomerates | Corporate Officer/Principal | |
Vattenfall AB
 Vattenfall AB Electric UtilitiesUtilities Vattenfall AB engages in the generation, distribution, and sale of heat and electricity. It operates through the following segments: Heat, Customers and Solutions, Wind, Power Generation, and Distribution. The company was founded in 1909 and is headquartered in Solna, Sweden. | Electric Utilities | General Counsel | |
| Stiftelsen Swecare | Director/Board Member | ||
| DEDICARE AB | Other Consumer Services | Director/Board Member | |
NovaSAID AB
 NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman | |
| Swedish Standards Institute | Director/Board Member | ||
| AB Stokab | General Counsel | ||
Swedish Medtech Service AB
 Swedish Medtech Service AB Miscellaneous Commercial ServicesCommercial Services Swedish Medtech Service AB is an association for medical technology in Sweden that brings together over 200 member companies to make Sweden the most attractive country for medical technology companies. The Swedish company's focus is on collaboration and they have a set of rules called "Samverkansreglerna". Anna Lefevre Skjöldbrand has been the CEO of the private company since 2005. | Miscellaneous Commercial Services | Chief Executive Officer | |
| JUNIPER PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Executive Officer | |
Sweden Medtech4health AB
 Sweden Medtech4health AB Miscellaneous Commercial ServicesCommercial Services Sweden Medtech4health AB is a strategic innovation program for medical technology that serves as a national arena for research and innovation on artificial intelligence for medical image analysis. The private company is based in Stockholm, Sweden. The Swedish company aims to be a catalyst for more medical technology ideas in healthcare, an efficient healthcare provider, and a strengthened medical technology industry. | Miscellaneous Commercial Services | Chairman | |
A.A.G. Aalborg Gummivarefabrik A/S
 A.A.G. Aalborg Gummivarefabrik A/S Miscellaneous ManufacturingProducer Manufacturing A.A.G. Aalborg Gummivarefabrik A/S is a holding company engage in manufacturing and processing technical rubber products. Its products include sheeting and plates, profiles, gaskets, pur and plastic, stable mats, mats and flooring, polyvinyl chloride doors, and accessories. It also offers items such as vibration insulators, rubber protectors and footings, custom made fender, polyurethane, playgrounds, damper, and scraper flooring solutions. The company was founded on June 29, 1979 and is headquartered in Norresundby, Denmark. | Miscellaneous Manufacturing | Corporate Officer/Principal | |
| University of the Witwatersrand | College/University | Graduate Degree | |
| Rhodes University | College/University | Undergraduate Degree | |
Pharmathen International SA
 Pharmathen International SA Pharmaceuticals: MajorHealth Technology Pharmathen was founded in 1969 in Athens, as a private pharmaceutical company, and is focused on the development and marketing of pharmaceuticals, with a strong position in generics. With 3 state of the art research laboratories and 2 manufacturing units, Pharmathen is a completely vertically integrated company and its activities extend from the development of pharmaceutical products up to their distribution. The company's human resources works in the sectors of Research & Development (R&D), production and distribution of drugs to different countries worldwide. Now, Pharmathen's products are approved in all EU markets and distribution rights have been granted to the largest pharmaceutical companies in the world, particularly in Europe, the United States of America and Canada. | Pharmaceuticals: Major | Director/Board Member | |
Gesynta Pharma AB
 Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Biolipox AB
 Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
| MOBERG PHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
| Stockholm School of Economics | College/University | Graduate Degree | |
| BIOSERVO TECHNOLOGIES AB | Medical Specialties | Director/Board Member | |
| The Boston Consulting Group AB | Corporate Officer/Principal | ||
| COCIR | Director/Board Member | ||
| Pfizer AB | Sales & Marketing | ||
| Läkemedelsindustriföreningens Service AB | Director/Board Member | ||
| MedTech Europe | Director/Board Member | ||
| E-Hälsomyndigheten | Director/Board Member |
Statistiche
Distribuzione geografica
| Svezia | 40 |
| Danimarca | 3 |
| Stati Uniti | 3 |
| Sud Africa | 3 |
| Belgio | 3 |
Settori
| Health Technology | 15 |
| Consumer Services | 10 |
| Commercial Services | 7 |
| Finance | 4 |
| Electronic Technology | 3 |
Posizioni
| Director/Board Member | 227 |
| Corporate Officer/Principal | 69 |
| Chairman | 50 |
| Independent Dir/Board Member | 46 |
| Chief Executive Officer | 29 |
Contatti più connessi
- Borsa valori
- Insiders
- Fredrik Järrsten
- Connessioni Società
